Hospital Medicine Unplugged

In this episode of Hospital Medicine Unplugged, we cut straight into heparin-induced thrombocytopenia (HIT)—the paradoxical clotting disorder that flips heparin from anticoagulant to prothrombotic trigger. Fast recognition and decisive action save lives here.
The first move: stop all heparin—IV, subQ, flushes, even coated catheters—and immediately start a therapeutic-dose, non-heparin anticoagulant. Never “hold and watch.” This isn’t a bleeding problem; it’s a thrombin storm.
Diagnosis is clinical plus confirmatory. Use the 4Ts score to judge pretest probability:
Low → HIT unlikely, continue heparin.
Intermediate/high → stop heparin, order PF4–heparin ELISA, and begin argatroban or another non-heparin anticoagulant.If ELISA is positive, confirm with a serotonin release assay (SRA) when available. High optical density (>2.0) + high 4Ts score = treat as HIT even without SRA.
Typical onset: platelet drop >50% around days 5–10 of heparin exposure. Rapid-onset HIT hits within 24 h in those with recent heparin exposure; delayed-onset can appear days after stopping therapy.Clinical red flags: thrombocytopenia + new thrombosis (venous > arterial), skin necrosis, or systemic reaction to heparin bolus. Bleeding is rare.
Pathophysiology snapshot: IgG antibodies bind PF4–heparin complexes → FcγRIIa activation → platelet aggregation + microparticle release → runaway thrombin generation. Result: thrombosis despite low platelets.
Treatment—anticoagulate boldly but wisely:
Argatroban: IV, hepatic clearance—first-line in renal failure or critical illness.
Danaparoid: Xa inhibitor, adjust for renal function.
Fondaparinux: off-label, effective in stable patients with good kidneys.
Bivalirudin: option for combined hepatic/renal dysfunction.
DOACs (rivaroxaban, apixaban, dabigatran): emerging outpatient or post-stabilization option—no monitoring, convenient, growing evidence base.
Warfarin warning: never start during acute HIT—risk of venous limb gangrene and limb loss. Begin only after platelets ≥150 × 10⁹/L, overlap with parenteral agent ≥5 days, and confirm INR stability before stopping the bridge.
Duration:
Isolated HIT (no thrombosis): until platelet recovery (~4 weeks max).
HIT with thrombosis: 3 months, same as provoked VTE.
Monitoring:Trend platelet counts every 2–3 days from day 4–14 of heparin exposure, repeat imaging for occult DVT, and follow aPTT or anti-Xa levels per chosen agent. Avoid platelet transfusions unless bleeding or procedure-bound.
Complications to dodge: DVT, PE, arterial occlusion, limb gangrene, adrenal vein thrombosis, and death (mortality 5–10%). Thrombosis may even precede thrombocytopenia—never wait for the count to crash before acting.
Prognosis: sharp decline in mortality when heparin is stopped early and non-heparin anticoagulation begins promptly. Platelets rebound within a week; clot risk fades over several weeks.
Prevention pearls:Prefer LMWH over UFH whenever possible (10× lower HIT risk). Limit duration, avoid heparin flushes, and monitor platelets in high-risk patients—especially cardiac, orthopedic, and ICU cohorts.
Fast, structured, and decisive—stop heparin, start argatroban (or equivalent), confirm with labs, and bridge only after platelets recover. HIT is a clotting crisis disguised as thrombocytopenia—catch it, treat it, and keep the thrombin storm from winning.

In this episode of Hospital Medicine Unplugged, we sprint through pheochromocytoma—confirm biochemically, block before you cut, resect definitively, and guard the perioperative hemodynamics.
We open with the do-firsts: biochemical confirmation (plasma-free or 24-h urine fractionated metanephrines/normetanephrines; >3× ULN is highly suggestive), then localize with adrenal-protocol CT or MRI. Reserve functional imaging (MIBG, SSTR/FDG PET) for suspected multifocal/metastatic disease. Genetic counseling/testing for all patients—heritability is high and changes management.
Pre-op preparation—build the alpha-first backbone:• Alpha-blockade for 7–14 days (phenoxybenzamine or selective α1: doxazosin/terazosin) titrated to low-normal BP.• Aggressive volume repletion + high-salt diet to reverse catecholamine-induced contraction and prevent post-op hypotension.• Add beta-blocker only after adequate alpha-blockade (e.g., metoprolol/atenolol) to tame tachycardia—never before.• Adjuncts: dihydropyridine CCBs or metyrosine for difficult control.• Avoid triggers of catecholamine crisis (e.g., pre-alpha β-blockade, glucocorticoids without ruling out pheo, TCAs/MAOIs, metoclopramide).
Definitive treatment—cut smart:• Minimally invasive adrenalectomy for localized, resectable disease when feasible.• Cortical-sparing surgery can be considered in bilateral/familial cases to reduce lifelong steroid dependence (balance with recurrence risk).• Intra-op surges: control with IV phentolamine, nitroprusside, or nicardipine; arrhythmias with esmolol or lidocaine.
When it’s not resectable or is metastatic:• Maintain alpha-blockade for secreting tumors.• Systemic therapy menu: HSA iobenguane I-131 (MIBG+), PRRT (SSTR+), targeted agents (e.g., belzutifan, cabozantinib, selpercatinib for RET+), sunitinib, somatostatin analogs, and chemotherapy (CVD or temozolomide).• Palliative RT for symptomatic or oligometastatic sites; enroll in clinical trials when possible.
Crisis playbook—stabilize before the knife:• Immediate alpha-blockade and IV vasodilators (phentolamine, nitroprusside, nicardipine); treat arrhythmias with esmolol (post-alpha) or lidocaine.• Delay surgery until medically stabilized; for refractory shock, consider mechanical circulatory support (e.g., VA-ECMO).
Post-op vigilance:• Watch for hypotension (give fluids) and hypoglycemia (dextrose), driven by rebound insulin secretion.• Post-op metanephrines (plasma or 24-h urine) to confirm cure or detect residual disease.• Long-term surveillance, especially in hereditary syndromes.
Pearls & pitfalls you don’t want to meet:• Block before you cut—and beta only after alpha.• Find and stop crisis-triggering meds early.• Don’t skip genetics—it guides extent of surgery, surveillance, and family screening.• Use functional imaging selectively to stage and to qualify for MIBG/PRRT.• Plan for hemodynamic lability intra-op and metabolic swings post-op.
We close with the system moves: a pheo bundle that (1) reflexes metanephrines for high-probability phenotypes; (2) auto-consults endocrine + endocrine surgery + anesthesia; (3) standardizes alpha-blockade + salt/volume protocol with β-add-on rules; (4) flags crisis triggers in the MAR; (5) prebooks imaging (adrenal CT/MRI ± functional); (6) preps OR vasodilator/antiarrhythmic infusions; (7) routes unresectable/metastatic cases to MIBG/PRRT/targeted therapy boards; (8) locks in post-op glucose/BP monitoring and metanephrine recheck.
Bottom line: Confirm biochemically, alpha-block and replete, resect with a plan, and monitor relentlessly.

In this episode of Hospital Medicine Unplugged, we sprint through heparin-induced thrombocytopenia (HIT)—recognize early, stop heparin immediately, and start full-dose non-heparin anticoagulation to prevent limb- and life-threatening thrombosis.
We open with the do-firsts: discontinue ALL heparin (including flushes, heparin-coated lines) and start a therapeutic-dose alternative—not prophylactic dosing—because HIT is prothrombotic even without visible clots.
Call the probability before the proof: use the 4Ts score (thrombocytopenia, timing, thrombosis/skin lesions, other causes). Low score → HIT unlikely (keep heparin, monitor). Intermediate/high → stop heparin, start non-heparin anticoagulant, send labs. Confirm with PF4/heparin IgG immunoassay and, when available, a functional assay (e.g., SRA) to validate platelet-activating antibodies.
Treatment—build the non-heparin backbone:• Argatroban (DTI): hepatic clearance—go-to in renal insufficiency or ICU, short half-life; monitor aPTT; mind INR inflation when bridging to warfarin.• Danaparoid (anti-Xa): IV/SC; monitor anti-Xa; adjust in renal impairment; >90% success in cohorts.• Bivalirudin (DTI): handy peri-procedurally or with mixed organ dysfunction.• Fondaparinux (anti-Xa, off-label): favored in stable patients with good renal function.• DOACs (off-label, growing evidence): consider after platelet recovery/stabilization in suitable, stable patients for convenience and cost-effectiveness.
Warfarin warning: Never start in acute HIT. Wait until platelets >150×10⁹/L and stable for ≥2 days, then overlap with the alternative anticoagulant; early VKA can trigger venous limb gangrene.
Risk-adapted moves:• Admit if severe thrombocytopenia, thrombosis, rapid fall, or high bleeding/procedural needs.• Monitor platelets q2–3 days from day 4–14 of heparin exposure (earlier if prior exposure).• Screen for silent clots—four-limb ultrasound is reasonable in acute HIT.• Avoid platelet transfusions unless life-threatening bleeding or an urgent procedure.
Timing pearls: classic onset day 5–10, rapid-onset within 24 h with recent heparin exposure, delayed-onset after stopping heparin, and rare spontaneous/autoimmune HIT—keep your radar on.
Complications you don’t want to meet: DVT/PE (most common), arterial thrombosis/limb ischemia, skin necrosis at injection sites, adrenal vein thrombosis, and systemic reactions after heparin bolus. Bleeding is uncommon—HIT is a clotting disorder.
Duration that sticks:• Isolated HIT (no thrombosis): treat until platelet recovery (some extend to ~4 weeks in select higher-risk cases).• HIT with thrombosis: ~3 months of anticoagulation.
Medication pitfalls: prophylactic dosing (under-treats), premature warfarin, missed heparin sources (flushes/catheters), and ignoring organ function when choosing argatroban/danaparoid/fondaparinux/DOACs.
We close with the system moves: a HIT bundle that (1) auto-stops heparin (including hidden sources); (2) defaults to therapeutic-dose non-heparin anticoagulation tailored to renal/hepatic status; (3) scores 4Ts and reflexes PF4 ELISA ± functional assay; (4) screens for occult thrombosis; (5) blocks early warfarin and mandates overlap; (6) standardizes monitoring (aPTT/anti-Xa, platelets); and (7) educates teams that HIT ≠ bleeding—it's a thrombin storm.
Bottom line: Stop heparin now, treat with full-dose non-heparin anticoagulation, delay and overlap warfarin, confirm with targeted labs, and hunt for clots.

In this episode of Hospital Medicine Unplugged, we spotlight vitamin D deficiency in hospitalized patients—who’s at risk, how to diagnose, and when (and how) to treat.
We start with definitions that matter: deficiency = <20 ng/mL, severe = <12 ng/mL, though the 2024 Endocrine Society now urges individualized assessment over rigid cutoffs. Hospital patients—especially the elderly, critically ill, malnourished, NPO, obese, or post-bariatric—sit at the crossroads of low intake, limited sunlight, and altered metabolism.
Mechanisms and impact: Vitamin D drives calcium absorption, bone mineralization, and immune regulation. Deficiency unleashes secondary hyperparathyroidism, bone demineralization, muscle weakness, and immune dysfunction. In hospital cohorts, deficiency predicts higher infection rates, longer stays, and greater mortality—but causation remains unproven.
Who to test: Skip universal screening; focus on high-risk groups—osteoporosis, CKD, liver disease, malabsorption, obesity, or meds that alter vitamin D metabolism (e.g., anticonvulsants, rifampin, glucocorticoids). Use LC-MS/MS when possible for accurate 25(OH)D measurement.
Clinical manifestations: Watch for proximal muscle weakness, diffuse bone pain, falls, fractures, delirium, and infections. Inflammatory markers (CRP/WBC) rise as vitamin D falls. Severe deficiency (<10–12 ng/mL) portends functional decline and higher short-term mortality.
Management—targeted, not universal:• Repletion: Vitamin D3 (cholecalciferol) preferred—5,000 IU daily × 8–12 weeks or 50,000 IU weekly × 8 weeks; then 1,000–2,000 IU daily for maintenance.• Severe deficiency / high-risk: Consider loading dose (e.g., 300,000–600,000 IU once), followed by daily maintenance.• Malabsorption or CKD: May require active forms (calcitriol) or parenteral options.• ICU patients: High-dose vitamin D3 (540,000 IU) corrects levels but doesn’t cut mortality or LOS (VITdAL-ICU, VIOLET). Subgroups with <12 ng/mL may benefit—ongoing trials (VITDALIZE) aim to clarify.• Obesity: Sequestration demands 2–3× higher doses (up to 7,000 IU/day or 50,000 IU/week).
Monitoring:Recheck 25(OH)D after 8–12 weeks; monitor calcium, phosphate, PTH if symptomatic or on high-dose therapy. Avoid retesting <6 months during stable maintenance unless clinically indicated.
Toxicity (rare but real): Think hypercalcemia + suppressed PTH when 25(OH)D >150 ng/mL. Stop supplements, hydrate aggressively, and treat with loop diuretics, bisphosphonates, or steroids if severe.
Drugs and interactions:• ↓ Absorption: cholestyramine, orlistat.• ↑ Metabolism: phenytoin, carbamazepine, rifampin, steroids.• ↑ Toxicity risk: thiazides + calcium/vitamin D combo → hypercalcemia.
Hospital outcomes: Deficient patients stay longer (↑LOS by ~1–2 days), face higher infection risk, and have 2–3× higher mortality. Trials show no universal survival benefit, but severe deficiency correction may reduce infection and death in targeted groups.
Special populations:• Elderly/institutionalized: 800–2,000 IU/day; mortality reduction modest but consistent.• Malnourished/NPO: weekly 60,000 IU × 5 weeks, then 2,000 IU/day.• Post-bariatric: ≥2,000 IU/day + calcium + regular monitoring.• Pregnant/lactating: 600–5,000 IU/day depending on risk.• Obese: up to 7,000 IU/day; monitor response.
Bottom line: Don’t blanket-dose—target smartly. Identify high-risk inpatients, correct true deficiency, avoid overshoot, and watch calcium. Vitamin D won’t cure critical illness—but in the severely deficient, it just might tilt the odds toward recovery.

In this episode of Hospital Medicine Unplugged, we run the playbook for small bowel obstruction (SBO)—triage fast, resuscitate early, image smart, don’t miss strangulation, and know when to operate.
We open with the do-firsts: IV access + balanced crystalloids, labs (CBC, electrolytes, creatinine, lactate), strict NPO, NG tube for decompression when vomiting/distended, and analgesia/antiemetics. Broad antibiotics if fever, leukocytosis, peritonitis, or suspected perforation.
Diagnosis & imaging: CT abdomen/pelvis with IV contrast is the gold standard—confirms SBO, finds the transition point, and flags closed-loop or ischemia (reduced wall enhancement, mesenteric edema, free fluid, pneumatosis, portal venous gas). Plain films are adjuncts only. Trend lactate but remember: a normal value doesn’t exclude ischemia.
Who needs the OR now? Peritonitis, hemodynamic instability, CT evidence of ischemia/closed loop, or incarcerated hernia → emergent surgery. Time is bowel.
Nonoperative lane (stable, no peritonitis/ischemia/closed loop): bowel rest, NG decompression, fluids/electrolytes, serial exams and labs. Water-soluble contrast (Gastrografin) protocols after decompression are both diagnostic and therapeutic—accelerate resolution and shorten length of stay; lack of contrast progression at 8–24 h signals likely failure of conservative care.
Clock management: a nonoperative trial should not exceed ~72 hours in adhesive SBO without red flags; beyond that, the risk of resection and complications rises. Predictors of failure: persistent pain/tachycardia, ongoing NG outputs without clinical improvement, no contrast progression, no small-bowel feces sign on CT, increasing free fluid, or rising lactate.
Risk & etiology snapshot: Adhesions (60–75%) lead, then hernias (~10%), neoplasm (~5%), Crohn’s (~5%). In a “virgin abdomen,” think malignancy/internal hernia/bezoar, though adhesions still common—keep your threshold for earlier exploration lower.
Surgical lane: laparoscopy in selected stable patients (less morbidity/shorter LOS); open for hostile abdomens, dense adhesions, suspected ischemia/perforation, or instability. Principles: release the transition, assess viability, resect only nonviable bowel, consider adhesion barriers and meticulous technique to reduce recurrence.
Special plays:• Crohn’s: prioritize medical optimization; operate for strictures unresponsive to therapy, fistula, abscess, or ischemia; consider strictureplasty where appropriate.• Hernia-related SBO: urgent repair—don’t delay for prolonged conservative trials.• Malignancy: tailor to disease burden—resection, bypass, or stent in selected cases; align with goals of care.
Monitoring that matters: strict I/O, daily weights, electrolytes (K/Mg/Phos), renal function, and serial abdominal exams. Early nutrition planning (enteral if possible) for prolonged courses. Prevent aspiration in high-risk patients.
Medication pitfalls: avoid routine opioids without a reassessment plan (masking peritonitis), skip prokinetics in mechanical SBO, be cautious with large fluid loads in the elderly/renal disease—resuscitate, then reassess.
We close with the system moves: an SBO bundle that (1) front-loads CT with IV contrast; (2) standardizes NG + fluid/electrolyte orders; (3) embeds a Gastrografin pathway with timed films and a 72-hour stop-point; (4) auto-alerts surgery at triage with shared daily checkpoints; (5) flags closed-loop/ischemia language in radiology reports; (6) builds a hernia check into every exam; (7) uses discharge prevention tools—adhesion reduction strategies and patient education.
Bottom line: resuscitate early, CT to classify, contrast-guided conservative care for stable adhesive SBO, operate without delay for ischemia/closed loop/failure to progress—because in SBO, timing is the difference between recovery and resection.

In this episode of Hospital Medicine Unplugged, we tackle Takotsubo cardiomyopathy (TTC)—spot the mimic fast, stabilize without harming LVOTO, prevent thromboembolism, and plan recovery.
We open with the do-firsts: treat like ACS until proven otherwise—ECG, troponin, CXR, labs; urgent coronary angiography to exclude obstruction. Then confirm with imaging: TTE for pattern (apical ballooning most common), complications (LVOTO, MR, RV involvement, LV thrombus). Add CMR if the picture is hazy (edema, typically no LGE) or recovery lags.
Diagnosis in one breath: transient LV wall-motion abnormality beyond a single vascular territory + no obstructive CAD + new ECG changes/troponin bump + exclude myocarditis/pheochromocytoma. Triggers skew postmenopausal women; physical stressors dominate in-hospital cases and often predict worse outcomes.
Risk-stratify for monitored care (any = step up care/consider ICU): shock or LVOTO, LVEF ≤35%, apical ballooning with akinesis, RV involvement, malignant arrhythmias, large apical aneurysm/“sack,” active cancer, sepsis/neurologic trigger, older age, male sex. Expect most complications in the first 72 hours.
Acute management—two lanes:
• If no LVOTO (most): gentle diuresis for congestion; ACEi/ARB, beta-blocker, loop diuretic as needed. Oxygen, electrolytes, QTc vigilance.• If LVOTO present/suspected: avoid inotropes/vasodilators; give cautious IV fluids, short-acting beta-blocker to blunt gradient; for hypotension, phenylephrine is reasonable. Consider IABP/temporary MCS for refractory shock after correcting LVOTO physiology.
Anticoagulation: treat documented LV thrombus (typically heparin → oral anticoagulation for ~3 months, repeat imaging). Consider prophylactic anticoagulation when apical ballooning + LVEF ≤30–35%, marked apical akinesis, or very high BNP—balance against bleeding risk. Always re-image to guide duration.
Arrhythmia playbook: correct K/Mg, avoid QT-prolongers, continuous telemetry; torsades → IV magnesium, overdrive pacing if needed. AF—rate control first; anticoagulate per standard stroke risk and TTC thrombus risk.
Complications you don’t want to miss: acute HF/pulmonary edema, cardiogenic shock, stroke/embolism, VT/VF, LV rupture (rare), RV involvement. Mortality rivals STEMI in high-risk subsets—this is not benign.
Recovery & follow-up: LV function usually normalizes within weeks. Recheck TTE at 1–2 weeks and 4–8 weeks. Continue ACEi/ARB ± beta-blocker for 2–3 months, then reassess; longer if LVEF or symptoms lag. Delayed recovery (≥10 days), physical triggers, or comorbidity → closer follow-up, cardiac rehab, and psychosocial support. Recurrence happens—beta-blockers may reduce long-term mortality/recurrence; encourage stress-modulation strategies and trigger control.
Medication pitfalls: catecholamine inotropes in LVOTO (collapse risk), aggressive vasodilators, QT-prolonging drugs, and unnecessary dual antiplatelet therapy once ACS is excluded (unless stented). Anticoagulate smartly—image-guided start/stop.
We close with the system moves: a TTC bundle that (1) auto-fires ACS pathway → angiography; (2) early TTE with LVOTO screen, RV look, and apex thrombus sweep; (3) LVOTO vs non-LVOTO branches with order sets; (4) telemetry + QTc protocol; (5) anticoagulation decision support for high-risk apical ballooning and confirmed thrombus; (6) 72-hour complication watch; (7) CMR when diagnosis is uncertain or recovery lags; (8) discharge plan with 2–8 week imaging, 2–3 months HF meds, and stress-trigger aftercare.
Bottom line: recognize the ACS mimic, image early, treat LVOTO carefully, protect from clot, and plan recovery with re-imaging—that’s how you make Takotsubo truly transient.

In this episode of Hospital Medicine Unplugged, we sprint through cerebral venous sinus thrombosis (CVST)—diagnose fast, anticoagulate early (even with ICH), escalate wisely, and individualize duration.
We open with the do-firsts: therapeutic heparin now—LMWH preferred for predictable dosing and lower HIT risk; UFH is fine if procedures are likely or renal function is tenuous. Anticoagulate even when intracranial hemorrhage is present unless there’s a specific contraindication (e.g., massive hematoma with expansion risk, HIT/VITT). Get MRI/MRV (or CTV when MRI’s a no-go) to confirm site/burden and look for venous infarction/hemorrhage.
Transition & duration: once stable, switch to oral anticoagulation—DOACs or warfarin are both acceptable. Treat 3–12 months in most; extend or make indefinite with persistent risks (thrombophilia, active cancer, recurrent VTE). Don’t chase recanalization to set duration—radiographic changes ≠ outcomes.
When the course bends: endovascular therapy (mechanical thrombectomy ± local lytics) is not routine—reserve for clinical deterioration despite adequate anticoagulation or when anticoagulation is contraindicated, and do it in experienced centers. Decompressive hemicraniectomy can be lifesaving for impending herniation/refractory intracranial hypertension from large venous infarcts.
Seizures & ICP: start anticonvulsants after a first seizure (or with parenchymal lesions/high risk); no prophylaxis otherwise. For edema/ICP, skip glucocorticoids, acetazolamide, and mannitol—evidence doesn’t support them here; avoid dehydration that could worsen thrombosis.
Special situations you must not miss:• HIT/VITT: avoid all heparins, use non-heparin anticoagulants (e.g., argatroban, bivalirudin, fondaparinux, DOACs where appropriate) and IVIG for VITT, with hematology on board.• Pregnancy/postpartum: favor LMWH throughout, involve obstetrics; DOACs generally avoided in pregnancy.• Malignancy/IBD/infection/COVID-associated CVST: anticoagulate as above; tailor duration to ongoing risk.
Monitoring that matters: tight neuro checks, watch for worsening headache, papilledema, seizures, encephalopathy. Trend CBC/platelets, coagulation, creatinine; surveil for bleeding. Repeat imaging if symptoms progress or to document status at 3–6 months (not to dictate duration).
Workup & risk framing: screen for provoking factors (OCPs, pregnancy, dehydration, surgery/immobility, infection, malignancy) and targeted thrombophilia testing once off acute-phase confounders. Counsel on risk modification (hormonal therapy, dehydration, prolonged immobility).
System moves for a safer pathway:
Anticoagulate on diagnosis (LMWH first line).
MRI/MRV or CTV to confirm, map thrombus, and detect venous infarct/ICH.
Early ICU/stroke-unit care for severe cases; manage seizures if they occur.
Oral anticoagulant transition with 3–12 mo default; longer when risks persist.
Reserve thrombectomy for refractory deterioration; decompress for herniation.
No routine steroids/diuretics for ICP; avoid prophylactic AEDs.
Tailor for HIT/VITT/pregnancy/cancer, and set a follow-up plan.
We close with the CVST mantra: treat the clot, not the bleed—start anticoagulation early, escalate selectively, individualize duration, and avoid therapies that don’t help. Most patients walk back to independence when we get these steps right.

In this episode of Hospital Medicine Unplugged, we sprint through hematuria in the hospital—classify fast, stabilize what’s dangerous, risk-stratify smartly, and image with purpose.
We open with the do-firsts: confirm gross vs. microscopic (≥3 RBC/HPF) on a proper urinalysis; repeat if contamination or a transient cause is likely. Don’t blame anticoagulation—it can unmask disease, not explain it away. Take a tight history (infection, stones, trauma/instrumentation, menstruation, exercise, meds, malignancy risks) and exam (vitals, bladder distention, CVA tenderness, external sources).
Red flags that change the room: clot retention/obstruction, hemodynamic instability, sepsis, AKI, coagulopathy, uncontrolled pain. Actions: large-bore catheter → manual/continuous bladder irrigation, resuscitate, cultures/antibiotics if infected, reverse coagulopathy when appropriate, and urgent urology.
Source matters—sort glomerular vs. nonglomerular:• Glomerular clues: dysmorphic RBCs/acanthocytes, RBC casts, proteinuria, renal dysfunction → nephrology; think IgA nephropathy, vasculitis, lupus.• Nonglomerular clues: isomorphic RBCs ± clots; think stones, infection, BPH, tumors, trauma → urology.
Risk stratify for cancer:• High risk (e.g., gross hematuria, age ≥35–40, male, smoking, occupational exposures, prior pelvic RT, chronic infection, indwelling catheter) → expedited cystoscopy + upper-tract imaging.• Lower risk microhematuria → repeat UA after treating reversible causes; escalate if persistent.
Imaging that earns its keep:• CT urography for high-risk patients and when malignancy/upper-tract pathology is on the table.• Renal & bladder ultrasound for low/intermediate risk to spare contrast/radiation; pair with cystoscopy when indicated.• Noncontrast CT for suspected stones.• Remember: cystoscopy is essential for bladder cancer—imaging can’t replace it.
Diagnostic pathway that sticks:
Confirm hematuria correctly; exclude UTI/contamination.
Classify (gross vs. microscopic) and triage red flags.
Microscopy to split glomerular vs. nonglomerular and gauge proteinuria.
Risk-adapted imaging (US vs. CT urography) + cystoscopy per risk.
Refer: nephrology for glomerular features; urology for malignancy risk, obstruction, persistent unexplained cases.
Follow up persistent microhematuria with a plan—don’t lose patients to the void.
Infection & anticoagulation plays:• Treat UTI first, then recheck UA—persistent hematuria still needs a workup.• On anticoagulants/antiplatelets? Evaluate as usual; adjust or reverse only for clinically significant bleeding or procedures.
Admission triggers: retention, instability, sepsis, AKI, severe bleeding, coagulopathy, intractable pain, or inability to manage at home. In-house: I/O, bladder scans, trend hemoglobin/creatinine, and maintain VTE prophylaxis unless contraindicated.
Cost–quality compass:• Risk-stratified algorithms catch nearly all clinically significant cancers while reducing radiation, contrast exposure, and cost compared with one-size-fits-all CT.• Use shared decision-making for borderline cases and contrast risks.
We close with the hematuria mantra: stabilize first, classify precisely, let urine microscopy guide the lane, match imaging to risk, and scope the bladder when risk is real—because gross hematuria and high-risk microhematuria demand answers, not assumptions.